Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Glomerulonephritis Minimal Lesion: early-phase trial registry

1 of 1 indexed Glomerulonephritis Minimal Lesion trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Glomerulonephritis Minimal Lesion: 1 US clinical trial tracked, 1 recruiting.

Glomerulonephritis Minimal Lesion is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi, running 1 of these trials.

Enrollment posture brief

Registry condition glomerulonephritis-minimal-lesion

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Glomerulonephritis Minim (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Glomerulonephritis Minimal Lesion

Glomerulonephritis Minimal Lesion lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Glomerulonephritis Minimal Lesion on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Glomerulonephritis Minimal Lesion is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Sanofi 1 trials

Named interventions

Most-linked intervention names on Glomerulonephritis Minimal Lesion records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

brivekimig Drug
1 trials
frexalimab Drug
1 trials
rilzabrutinib Drug
1 trials
placebo Drug
1 trials

US sites by state

Facility locations filed on Glomerulonephritis Minimal Lesion trials. A trial with sites in several states counts in each.

Texas 1 trials
New York 1 trials
Nevada 1 trials
New Mexico 1 trials
North Carolina 1 trials
Minnesota 1 trials
Michigan 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Glomerulonephritis Minimal Lesion page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Glomerulonephritis Minimal Lesion trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Sanofi sponsors the most Glomerulonephritis Minimal Lesion trials on record, review their full trial history before evaluating a specific study. See Sanofi's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glomerulonephritis Minimal Lesion condition card totals 1 registered trials; most-linked intervention brivekimig; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.